ASCAP Executive Chris Amenita Dies at 55

Chris Amenita
Chris Amenita
 

Christopher Amenita, who worked at ASCAP for more than a quarter-century, rising to senior vp broadcasting operations and new media licensing, died Aug. 3 of cancer. He was 55.

Amenita oversaw licensing negotiations for the performance rights group, which he joined in the mid-1980s. Based in New York, he was responsible for overseeing ASCAP’s development of audio fingerprinting technologies for use in the group’s performance tracking and was involved in the creation of ASCAP's website, and its New Media and Technology Department.

Before that, he was senior vp of ASCAP’s Enterprises Group, which focused on Internet licensing, the evaluation of emerging technologies surrounding the digital delivery of music and technologies and ventures.

 “Chris was one of the most beloved and respected members of the ASCAP senior management team and we all feel his loss profoundly,” ASCAP CEO John LoFrumento said. “He was a great strategic thinker who understood the complex issues our members face in today’s world. He was also one of the kindest and most generous of co-workers, always willing to mentor others.”

PHOTOS: Hollywood's Notable Deaths of 2012

A graduate of the New York Institute of Technology, Amenita was a regular on panels involving the impact of tech on the music and broader entertainment industries. The Long Island resident also served as chairman of The Digital Data Exchange -- a consortium of organizations that represent songwriters and publishers, digital service providers and record labels -- from its inception in May 2006 to November 2009 and continued to serve on its board.

Survivors include his wife, Bonnie; children Christopher Jr. and Lauren; his parents Thomas and Antoinette; brother Thomas and sister-in-law Jean; and his parents-in-law, Ed and Jody Murphy.

Mass will be celebrated at 9:45 a.m. Aug. 8 at St. Patrick’s Church in Huntington, Long Island. In lieu of flowers, the family asks that donations be made in Amenita’s name to the University of Texas M.D. Anderson Cancer Center: www.mdanderson.com

comments powered by Disqus